FindTrial
Sign In

Phase IIa study of T-5224 in RA patients

Phase IIa study of T-5224 in RA patients

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221322
Enrollment
Unknown
Registered
2010-12-01
Start date
2010-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : T-5224 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigation

Sponsors

Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Male or female. -Subject who have a diagnosis of Rheumatoid Arthritis by the ACR criteria. -Age greater or 20 years and less than 65 years old. -Subject who diagnosed to class 1-3 of Steinblocker dysfunction classification.

Exclusion criteria

Exclusion criteria: -Subject with autoimmune disease except RA and SS. -Subject who is pregnancy, has possibility of pregnancy, hopes for pregnancy, is suckling.

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Secondary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026